Summary of selected patient and disease characteristics
| Characteristic . | Value . |
|---|---|
| Sex, no. (%) | |
| Female | 90 (45) |
| Male | 110 (55) |
| Race/ethnicity, no. (%) | |
| Asian | 4 (2) |
| Black | 21 (11) |
| White, Hispanic | 5 (3) |
| White, non-Hispanic | 169 (85) |
| Hispanic, NOS | 1 (1) |
| AML onset, no. (%) | |
| De novo | 157 (79) |
| Secondary | 43 (22) |
| Favorable cytogenetics | 9 (5) |
| Risk group, no. (%) | |
| Intermediate | 106 (53) |
| Unfavorable | 39 (20) |
| Unknown | 46 (23) |
| FAB class, local diagnosis, no. (%) | |
| M0 | 10 (5) |
| M1* | 48 (24) |
| M2 | 63 (32) |
| M3 | 1 (1) |
| M4 | 51 (26) |
| M5 | 19 (10) |
| M6 | 1 (1) |
| M7 | 2 (1) |
| Other AML | 5 (3) |
| Age, median y (min-max) | 68 (56-88) |
| Marrow blasts, % (min-max) | 70 (10-99) |
| WBC count, ×109 (min-max) | 35 (0.7-298) |
| Peripheral blasts, %, (min-max) | 75 (0-99) |
| Characteristic . | Value . |
|---|---|
| Sex, no. (%) | |
| Female | 90 (45) |
| Male | 110 (55) |
| Race/ethnicity, no. (%) | |
| Asian | 4 (2) |
| Black | 21 (11) |
| White, Hispanic | 5 (3) |
| White, non-Hispanic | 169 (85) |
| Hispanic, NOS | 1 (1) |
| AML onset, no. (%) | |
| De novo | 157 (79) |
| Secondary | 43 (22) |
| Favorable cytogenetics | 9 (5) |
| Risk group, no. (%) | |
| Intermediate | 106 (53) |
| Unfavorable | 39 (20) |
| Unknown | 46 (23) |
| FAB class, local diagnosis, no. (%) | |
| M0 | 10 (5) |
| M1* | 48 (24) |
| M2 | 63 (32) |
| M3 | 1 (1) |
| M4 | 51 (26) |
| M5 | 19 (10) |
| M6 | 1 (1) |
| M7 | 2 (1) |
| Other AML | 5 (3) |
| Age, median y (min-max) | 68 (56-88) |
| Marrow blasts, % (min-max) | 70 (10-99) |
| WBC count, ×109 (min-max) | 35 (0.7-298) |
| Peripheral blasts, %, (min-max) | 75 (0-99) |
NOS indicates not otherwise specified; min-max, minimum-maximum.
*One patient (141020) had local diagnosis of myelodysplastic syndrome-refractory anemia with excess blasts but central review diagnosis of AML-M1 is included as AML-M1 in this analysis.